Search

This article presents silica nanoparticles for the sustained release of AMACR antibody-conjugated and free doxorubicin (DOX) for the inhibition of prostate cancer cell growth. Inorganic MCM-41 silica nanoparticles were synthesized, functionalized with phenylboronic acid groups (MCM-B), and capped with dextran (MCM-B-D). The nanoparticles were then characterized using Fourier-transform infrared spectroscopy, scanning electron microscopy, transmission electron microscopy, zeta potential analysis, nitrogen sorption, X-ray diffraction, and thermogravimetric analysis, before exploring their potential for drug loading and controlled drug release. This was done using a model prostate cancer drug, DOX, and a targeted prostate cancer drug, α-Methyl Acyl-CoA racemase (AMACR) antibody-conjugated DOX, which attaches specifically to AMACR proteins that are overexpressed on the surfaces of prostate cancer cells. The kinetics of sustained drug release over 30 days was then studied using zeroth order, first order, second order, Higuchi, and the Korsmeyer-Peppas models, while the thermodynamics of drug release was elucidated by determining the entropy and enthalpy changes. The flux of the released DOX was also simulated using the COMSOL Multiphysics software package. Generally, the AMACR antibody-conjugated DOX drug-loaded nanoparticles were more effective than the free DOX drug-loaded formulations in inhibiting the growth of prostate cancer cells in vitro over a 96 h period. The implications of the results are then discussed for the development of drug-eluting structures for the localized and targeted treatment of prostate cancer.

Introduction: Specific diagnosis which provides diagnostic, prognostic, and therapeutic information to guide patient care defines the primary goal of sarcoma management and care. The role of immunohistochemistry, using vimentin (mesenchymal linage marker) and cytokeratin (epithelial linage marker) as basic markers for diagnosis and classification of sarcomas for specific management strategies and prognosis was elucidated in the present study. Materials and Methods: Twenty four (24) archived paraffin wax processed tissue block sarcoma samples were randomly selected from the histopathology Laboratories and museums of the Nnamdi Azikiwe University Teaching Hospital (NAUTH) Nnewi and National hospital Abuja and necessary data obtained from records. Blocks were re-embedded with fresh paraffin wax and 3µ thick sections cut with the aid of a rotary microtome. Haematoxylin and Eosin staining method was employed to confirm diagnosis before proceeding to immunohistochemistry. Antibodies for vimentin and pancytokeratin were employed for immunohistochemistry while exposed mouse and rabbit specific horseradish peroxides/diaminobenzidine detection IHC kit was employed for immunostaining. Results: The mean age of patients was 26 years while the ages range from 11 to 48 years with 14 (58.3%) females and 10 (41.7%) males. Vimentin had strong positive immunoreactivity for all sarcoma samples whereas cytokeratin had positive immunoreactions for synovial sarcoma only, which also showed co-expression of both genes. Conclusion: Vimentin and cytokeratin may play vital role as basic biomarkers not only for diagnosis and characterization of sarcomas but for specific management regime and prognostication. However, IHC must be performed at high standard using appropriate antibodies, samples and reagents. Keywords: Sarcoma, immunohistochemistry, vimentin, cytokeratin, biomarker.

Objective: The objective of this study was to evaluate nuclear changes in the buccal epithelial cells of commercial bus drivers using tobacco in Nnewi. Tobacco use constitutes a major risk factor of oral lesions, due to its genotoxic and mutagenic effects on the buccal cavity epithelial cells. Methods: One hundred and twenty-three subjects, consisting of 83 tobacco users (test group) and 40 tobacco and alcohol non-users (control group) were recruited for this cross-sectional study. Buccal smear was obtained from each participant, processed, and stained with the Papanicolaou staining method. Two hundred cells were counted for each stained slide and the percentage of various nuclear changes determined, and the repair index calculated. Comparisons of nuclear changes between and within groups were carried out using the Kruskal–Wallis H-test with p

PURPOSE Anal cancer risk is substantially higher among HIV-infected men who have sex with men (MSM) as compared with other reproductive-age adults, but screening is rare across sub-Saharan Africa. We report the use of high-resolution anoscopy (HRA) as a first-line screening tool and the resulting early outcomes among MSM in Abuja, Nigeria. METHODS From August 2016 to August 2017, 424 MSM enrolled in an anal cancer screening substudy of TRUST/RV368, a combined HIV prevention and treatment cohort. HRA-directed biopsies were diagnosed by histology, and ablative treatment was offered for high-grade squamous intraepithelial lesions (HSIL). HRA proficiency was assessed by evaluating the detection of squamous intraepithelial lesions (SIL) over time and the proportion biopsied. Prevalence estimates of low-grade squamous intraepithelial lesions and HSIL with 95% CIs were calculated. Multinomial logistic regression was used to identify those at the highest risk of SIL. RESULTS Median age was 25 years (interquartile range [IQR], 22-29), median time since sexual debut was 8 years (IQR, 4-12), and 59% (95% CI, 54.2% to 63.6%) were HIV infected. Rate of detection of any SIL stabilized after 200 screenings, and less than 20% had two or more biopsies. Preliminary prevalence estimates of low-grade squamous intraepithelial lesions and HSIL were 50.0% (95% CI, 44.7% to 55.3%) and 6.3% (95% CI, 4.0% to 9.3%). HIV infection, at least 8 years since anal coital debut, concurrency, and external warts were independently statistically associated with SIL. CONCLUSION Proficiency with HRA increased with experience over time. However, HSIL detection rates were low, potentially affected by obstructed views from internal warts and low biopsy rates, highlighting the need for ongoing evaluation and mentoring to validate this finding. HRA is a feasible first-line screening tool at an MSM-friendly health care facility. Years since anal coital debut and external warts could prioritize screening.

Objective: To measure the transcript levels of Aurora kinases and compare them to their immunoreactivity patterns in prostate tumors. Materials and Methods: A total of 26 cases of prostate cancer (PCa) and 38 cases of benign nodular hyperplasia (BPH) were sampled from archived formalin-fixed paraffin-embedded tissues. Tissue sections were lysed, total RNA extracted and cDNA made by random hexamer priming while slide sections were immunostained for the kinases. Normalized relative quantitation was performed for all the kinases using real-time PCR on TaqMan chemistry. Results: The immunoreactivity profile showed 15.4, 53.8 and 30.7% positivity for Aurora kinases A, B and C in PCa cases, respectively, while the positivity was 76.3, 73.7 and 84.2% for the same kinases in BPH cases. The immunoreactivity was preponderant on epithelial tissue compared to stromal component. Conclusion: Aurora kinases were significantly overexpressed in BPH cases compared to PCa cases. At the transcript level, there was no significant differential expression in the kinases between PCa and BPH cases.

Introduction : Diagnosis of prostatic diseases with Immunohistochemistry still faces challenges because of the peculiar histology of the prostate and difference(s) in reactivity of Monoclonal antibodies (MoAb) to benign and malignant changes. Methods : Thirty (30) archived paraffin embedded tissue samples from primary prostate tumors (15 Benign Prostatic Hyperplasia (BPH) and 15 Cancer of the prostate (CaP)) were sectioned at thickness of 5im and confirmed as BPH or CaP. Sections from each sample were stained by Immunohistochemistry using the Streptavidin-biotin method and using CK5/6, CK7, CK8,CK20 and Ki67 antibodies (Zymed Antibody products). Appropriate positive and negative controls for each antibody were setup alongside the test slides. Results : BPH samples were reactive to Ck5/6 (93.3%), Ck7 (80%) and Ck8 (100%). Only 13.3% of BPH samples were reactive to Ki67. The reactivity of Ck5/6, 7, 8 in CaP is a contrast with only 3(20%) of samples positive with Ck5/6, 2(13.3%) positive with Ck7 and 14(93.3%) with Ck8. While reactivity of Ck 8 is similar in BPH and CaP, no reaction was recorded in Ck 20 in both BPH and CaP.Ki67 was only reactive in 2(13.3) of BPH samples and 15(100%) of CaP. Only Ck 8 was expressed in both BPH and CaP. There was co-expression of Ck5/6, 7,8andKi67 in13.3%; Ck7and Ki67 in 13.3% in both BPH and CaP. Conclusion : The various cytokeratins are individually expressed in both BPH and CaP. Ck5/6 and Ck7 are co-expressed and may be used in the diagnosis of BPH, Ck5/6,7,8 and Ki67 are coexpressed in Prostatic adenocarcinoma and squamous cell carcinoma of the prostate while Ck8 and Ki67 are co-expressed and may be used for diagnosis of Prostatic adenocarcinoma alone.

We report a case of a possible association of schistosomiasis with Non-Hodgkins lymphoma. A 19 year old Nigerian lady presented with week long history of abdominal swelling and vomiting. Sonography of the abdominal cavity gave a diagnosis of colonic tumour. Resected portion of the ileum showed an ileoceacal mass appearing like an intususception. Histopathology initially revealed schistosomal ova and the adult worm in-copula, Immunohistochemistry however revealed that the mass was not just a granuloma, but a diffuse B-lymphocyte Non-Hodgkins lymphocytic lymphoma. The proximity of the schistosoma ova in the tissue sections suggests that schistosomiasis may have some effect on carcinogenesis. We therefore recommend that patients with chronic parasitic infestation, especially schistosomiasis, should be monitored more closely in view of the relevant emerging association between cancer and infections.

Introduction: Kaposi sarcoma poses problems in histological diagnosis because of its broad morphologic variants and similarity to many vasoproliferative lesions. Establishing diagnosis on the basis of tumour marker alone (especially a single result) is fraught with associated pitfalls because of the problem of non- specificity. Method: Fifteen (15) Kaposi sarcoma biopsies from seven (7) men and eight (8) women were used to find out the gene expression of vimentin, desmin, smooth muscle actin (SMA), S-100 and neuron specific enolase (NSE) in Kaposi sarcoma, Haematoxylin and eosin (H&E) method was used to confirm the diagnosis of Kaposi sarcoma in archival processed biopsies. Subsequently, Immunohistochemistry (IHC) was carried out to find out the expression of the antibodies listed. Results: Vimentin and SMA were found to be most reactive. Neuron specific enolase was mildly reactive while the rest were non-reactive. Conclusion: Only vimentin and SMA offer significant reactivity in the diagnosis of Kaposi sarcoma and are useful in undifferentiated neoplasms.